Skip to main content

Table 1 Demographic and Clinical Characteristics of 122 AKI Patients Admitted to the Intensive Care Unit

From: Continuous renal replacement therapy in patients with HIV/AIDS

 

Patients with AKI n = 122

Patients with CRRT n = 32

Patients without CRRT n = 90

p

Male(%)

112 (91.8)

31 (96.9)

81 (90)

0.452

Age(years)

41 (34–50)

42 (37–55.5)

41 (31–50)

0.137

Blood routine and biochemical items

 Lymphocyte count(× 109)

0.5 (0.3–0.92)

0.54 (0.34–1.10)

0.5 (0.30–0.80)

0.205

  Hemoglobin(g/L)

98.9 ± 27.4

90.7 ± 23.8

101.8 ± 28.1

0.048

  Albumin (g/L)

28.0 ± 5.8

29.3 ± 4.9

27.5 ± 6.1

0.154

 Total Bilirubin (u mol/L)

8.65 (5.38–13.43)

7.75 (5.03–15.33)

9.15 (5.4–13.43)

0.682

 Serum calcium(mmol/L)

1.92 (1.77–2.09)

2.00 (1.67–2.19)

1.92 (1.82–2.05)

0.375

Items related to HIV infection

 CD4 counts at ICU admission

23 (8–78)

37 (13–122)

15 (7–69)

0.043

  Patients with HAART

30 (24.6)

11 (34.4)

19 (21.1)

0.135

Items related to AKI

 The first Creatinine in Hospital (u mol/L) 72.7 (54–129.3)

 

220.1 (70.9–499.1)

64.5 (51.8–92.6)

<0.001

 The highest Creatinine before in ICU(u mol/L)48.9 (34.7–70.8)

 

194.2 (55.4–441.5)

42.1 (32.8–58.6)

<0.001

 The highest Creatinine during ICU(u mol/L) 159.6 (85.6–331)

 

375.4 (293.3–580.0)

121.6 (79.4–210.5)

<0.001

Complication

 Sepsis (%)

104 (85.2)

25 (78.1)

79 (87.8)

0.245

 Septic Shock(%)

74 (60.7)

19 (59.4)

55 (61.1)

0.863

 PCP (%)

71 (58.2)

12 (37.5)

59 (65.6)

0.006

 Respiratory Failure (%)

81 (66.4)

15 (46.9)

65 (72.2)

0.01

Multiple Organs Support Therapy

 The use of vasoactive agents (%)

81 (66.4)

22 (68.8)

59 (65.6)

0.742

 Duration of Mechanical ventilation (h)

131.5 (16–264)

141.5 (5–225.5)

124.5 (24–264.0)

0.788

Severity of illness

 SOFA score at ICU admission

8 (4–12)

12 (6–16)

7 (4–10)

<0.001

 APACHE-II score at ICU admission

20 (15–28)

28 (21–34)

18 (15–23)

<0.001

Outcome

 Death during in ICU

61 (50)

18 (56.3)

43 (47.8)

0.41

 Length of ICU stay (days), median (IQR)

9 (5–16)

8 (5–16)

9 (5–17)

0.616

 Length of hospital stay (days), median (IQR)

17 (9–30)

15 (7–21)

20 (10–34)

0.022

  1. ICU Intensive care unit, HIV Human immunodeficiency virus, HAART Highly Active Anti-Retroviral Therapy, PCP Pneumocystis carinii pneumonia, CRRT Continuous renal replacement therapy, SOFA, IQR Interquartile range, APACHE-II Acute physiology and chronic health evaluation, version II, SOFA Sequential organ failure assessment, GFR Glomerular Filtration Rate, MPV Mean Platelet Volume
  2. p Value < 0.05 was considered significant and is highlighted in bold